ZCA
CLVS

Zeke Capital Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Zeke Capital Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,412
Closed -$333K – 588
2019
Q1 		$333K Buy
+13,412
New +$336K 0.03% 449
2018
Q4 		– Sell
-9,134
Closed -$268K – 673
2018
Q3 		$268K Buy
+9,134
New +$354K 0.02% 539

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Zeke Capital Advisors's CLVS Position: Q2 2019 in Review

Zeke Capital Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 13,412 shares — an estimated $333K sold.

Zeke Capital Advisors first reported a position in CLVS in Q3 2018 and held it in 2 quarters. The position peaked at $333K in Q1 2019. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Zeke Capital Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Zeke Capital Advisors sold 13,412 Clovis Oncology, Inc. shares in Q2 2019, an estimated $333K.
  • Zeke Capital Advisors first reported a position in Clovis Oncology, Inc. in Q3 2018 and held it in 2 quarters.
  • Zeke Capital Advisors's Clovis Oncology, Inc. position peaked at $333K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Zeke Capital Advisors's 13F filing for Q2 2019, filed 24 Jul 2019.